Comparative Incidence of Postoperative Hemorrhage in Vitreoretinal Surgery in Patients on Anti-Coagulants
Authors:
- 1 July 2021
- journal article
- research article
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 52 (7) , 374-379
Abstract
Data regarding hemorrhagic complications of direct oral anticoagulants (DOACs) and vitreoretinal surgery are limited. Multicenter analysis of longitudinal, aggregated electronic health records of patients undergoing pars plana vitrectomy (PPV) with no prior history of ocular hemorrhage. Retrospective analysis of patients undergoing PPV between January 1, 2013, and December 31, 2019. The main outcomes were development of postoperative hemorrhagic complications within 1 month following vitreoretinal surgery. A total of 58,131 eyes underwent PPV, with 2,956 (5.1%) on anticoagulant medication prior to surgery. Eight hundred twenty-eight eyes (1.4%) developed a postoperative hemorrhage. Of eyes with anticoagulation use, 50 of 2,956 (1.29%) developed a hemorrhage, whereas 778 of 55,175 (1.41%) of the eyes with no prior anticoagulation use developed a postoperative hemorrhage (P = .2107). Use of DOACs prior to vitreoretinal surgery does not appear to be associated with increased rates of postoperative intraocular hemorrhage. [Ophthalmic Surg Lasers Imaging Retina. 2021;52:374–379.]Keywords
This publication has 30 references indexed in Scilit:
- Pre–Retinal Surgery Identification of Novel Anticoagulation and Antiplatelet AgentsOphthalmology Retina, 2018
- Antiplatelets and anticoagulants in vitreoretinal surgery, with a special emphasis on novel anticoagulants: a national survey and reviewGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- Peri‐operative management of anticoagulation and antiplatelet therapyBritish Journal of Haematology, 2016
- HEMORRHAGIC RISK OF VITREORETINAL SURGERY IN PATIENTS MAINTAINED ON NOVEL ORAL ANTICOAGULANT THERAPYRetina, 2016
- Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor TherapyCurrent Atherosclerosis Reports, 2015
- New oral anticoagulants and oculoplastic surgeryCanadian Journal of Ophthalmology, 2014
- Rivaroxaban: A New Oral Factor Xa InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Apixaban: an emerging oral factor Xa inhibitorJournal of Thrombosis and Thrombolysis, 2009
- Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplastyArchives of orthopaedic and trauma surgery, 2009
- Interactions of Warfarin with Drugs and FoodAnnals of Internal Medicine, 1994